But another genetic test, Oncotype DX, which USES a different technique to predict the recurrence of breast cancer, has not been submitted to the f.

The test was developed by Genomic Health, a California biotechnology company that sells a similar test called Oncotype Dx for women with breast cancer.

In a second study led by Albain, published in the journal Lancet Oncology, the team evaluated whether the Oncotype DX test can predict which women would benefit from chemotherapy.